Indinavir

Indinavir
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alberto Plate [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Indinavir is an antiretroviral agent and protease inhibitor that is FDA approved for the treatment of HIV infection in combination with other antiretroviral agents. Common adverse reactions include abdominal pain, heartburn, loss of appetite, nausea, taste sense altered, vomiting, neutrophil count abnormal, hyperbilirubinemia and headache.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

There is limited information regarding Indinavir FDA-Labeled Indications and Dosage (Adult) in the drug label.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Indinavir in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Indinavir in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding Indinavir FDA-Labeled Indications and Dosage (Pediatric) in the drug label.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Indinavir in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Indinavir in pediatric patients.

Contraindications

There is limited information regarding Indinavir Contraindications in the drug label.

Warnings

There is limited information regarding Indinavir Warnings' in the drug label.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Indinavir Clinical Trials Experience in the drug label.

Postmarketing Experience

There is limited information regarding Indinavir Postmarketing Experience in the drug label.

Drug Interactions

There is limited information regarding Indinavir Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): There is no FDA guidance on usage of Indinavir in women who are pregnant.
Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Indinavir in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Indinavir during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Indinavir in women who are nursing.

Pediatric Use

There is no FDA guidance on the use of Indinavir in pediatric settings.

Geriatic Use

There is no FDA guidance on the use of Indinavir in geriatric settings.

Gender

There is no FDA guidance on the use of Indinavir with respect to specific gender populations.

Race

There is no FDA guidance on the use of Indinavir with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Indinavir in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Indinavir in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Indinavir in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Indinavir in patients who are immunocompromised.

Administration and Monitoring

Administration

There is limited information regarding Indinavir Administration in the drug label.

Monitoring

There is limited information regarding Indinavir Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Indinavir and IV administrations.

Overdosage

There is limited information regarding Indinavir overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

Pharmacology

There is limited information regarding Indinavir Pharmacology in the drug label.

Mechanism of Action

There is limited information regarding Indinavir Mechanism of Action in the drug label.

Structure

There is limited information regarding Indinavir Structure in the drug label.

Pharmacodynamics

There is limited information regarding Indinavir Pharmacodynamics in the drug label.

Pharmacokinetics

There is limited information regarding Indinavir Pharmacokinetics in the drug label.

Nonclinical Toxicology

There is limited information regarding Indinavir Nonclinical Toxicology in the drug label.

Clinical Studies

There is limited information regarding Indinavir Clinical Studies in the drug label.

How Supplied

There is limited information regarding Indinavir How Supplied in the drug label.

Storage

There is limited information regarding Indinavir Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Indinavir |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Indinavir |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Indinavir Patient Counseling Information in the drug label.

Precautions with Alcohol

Alcohol-Indinavir interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

There is limited information regarding Indinavir Brand Names in the drug label.

Look-Alike Drug Names

There is limited information regarding Indinavir Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

Indinavir
CRIXIVAN® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3]; Associate Editor(s)-in-Chief: Mohamed Moubarak, M.D. [4]

Overview

Indinavir (IDV; trade name Crixivan, manufactured by Merck) is a protease inhibitor used as a component of highly active antiretroviral therapy (HAART) to treat HIV infection and AIDS.

Category

Protease inhibitor

US Brand Names

CRIXIVAN^®

FDA Package Insert

Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Dosage and Administration | How Supplied

Mechanism of Action

HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Indinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles.